- Recent Funding
- Investors
- Tavistock Life Sciences
Tavistock Life Sciences portfolio
Tavistock Life Sciences has 1 portfolio company on record at Recent Funding. Its most recent investment on record is Atreca's $125M Series B+ round in September 2018, alongside Wellington Management, Tekla Capital Management, Samsara Biocapital and 5 others. That company is in Health and bio.
What Tavistock Life Sciences invests in
- Health and bio · 1 · 100%
How Tavistock Life Sciences invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series B+ | 1 100% | $125M |
Share is of the 1 round on Recent Funding that name Tavistock Life Sciences. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Tavistock Life Sciences portfolio companies
| Company | Round with Tavistock Life Sciences | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series B+ · $125M | $181M | Feb 5, 2026 Series A |
Most frequent co-investors
WWellington Management1 shared round · last Sep 12, 2018
SSamsara Biocapital1 shared round · last Sep 12, 2018
AAisling Capital1 shared round · last Sep 12, 2018
BBoxer Capital1 shared round · last Sep 12, 2018
CCormorant Asset Management1 shared round · last Sep 12, 2018
TTekla Capital Management1 shared round · last Sep 12, 2018
RRedmile Group1 shared round · last Sep 12, 2018
EEcoR1 Capital1 shared round · last Sep 12, 2018
Similar investors
AAccelia Capital1 company · 1 deal in 12 mo
AAngel Academe1 company · 1 deal in 12 mo
BBioGenerator Ventures1 company · 1 deal in 12 mo
BBiospring Partners1 company · 1 deal in 12 mo
CColossa Ventures1 company · 1 deal in 12 moDDeepWork Capital1 company · 1 deal in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
Portfolio companies are the companies on Recent Funding with a round that lists Tavistock Life Sciences, which is a subset of its real portfolio. API: /api/v1/investors/tavistock-life-sciences (get a free API key). More: the most active VC firms and new venture capital funds.